Changes in cognition during the preclinical phase of Alzheimer's Disease: Findings from the Wisconsin Registry for Alzheimer's Prevention (WRAP)
The International Neuropsychological Society is approved by the American Psychological Association to sponsor continuing education for psychologists. The International Neuropsychological Society maintains responsibility for this program and its content.
- Summarize the techniques used to assess Alzheimer’s disease proteinopathy including imaging and biofluids.
- Describe the biological processes that appear to drive cognitive decline and their temporal scale in the presymptomatic stage of Alzheimer’s disease.
- Compare the relative value of a biological definition of AD to a clinical definition.
|Availability:||Date Available: 2022-10-18|
|You may obtain CE for this webinar at any time.|
|Offered for CE||Yes|
|Refund Policy||This webinar is not eligible for refunds|
|CE Credits 1.0|
The cognitively unimpaired stage of Alzheimer’s disease (AD) is quite long in duration, but the interval varies widely from person to person. This talk will describe some of the brain and cognitive changes that we have observed from over a decade of biomarker imaging within the Wisconsin Registry for Alzheimer’s Prevention (WRAP) and related studies. The talk will give an overview of the WRAP study including its approach to measuring cognition, and describe the approaches to biomarker imaging we and others use to characterize AD proteinopathy. I’ll describe how we have derived temporal information from biomarker imaging such that age of onset of AD proteinopathy and disease duration can be estimated. I’ll also describe some of the factors that influence age of onset and duration of the pre-symptomatic stage of AD duration of the pre-symptomatic stage of AD.
- Betthauser, T. J., Bilgel, M., Koscik, R. L., Jedynak, B. M., An, Y., Kellett, K. A., . . . Alzheimer's Disease Neuroimaging, I. (2022). Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts. Brain. doi:10.1093/brain/awac213
- Jack, C. R., Jr., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., . . . Contributors. (2018). NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement, 14(4), 535-562. doi:10.1016/j.jalz.2018.02.018
- Johnson, S. C., Koscik, R. L., Jonaitis, E. M., Clark, L. R., Mueller, K. D., Berman, S. E., . . . Sager, M. A. (2018). The Wisconsin Registry for Alzheimer's Prevention: A review of findings and current directions. Alzheimers Dement (Amst), 10, 130-142. doi:10.1016/j.dadm.2017.11.007
- Koscik, R. L., Betthauser, T. J., Jonaitis, E. M., Allison, S. L., Clark, L. R., Hermann, B. P., . . . Johnson, S. C. (2020). Amyloid duration is associated with preclinical cognitive decline and tau PET. Alzheimers Dement (Amst), 12(1), e12007. doi:10.1002/dad2.12007
- Schindler, S. E., Li, Y., Buckles, V. D., Gordon, B. A., Benzinger, T. L. S., Wang, G., . . . Xiong, C. (2021). Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. Neurology, 97(18), e1823-e1834. doi:10.1212/WNL.0000000000012775
Dr. Johnson receives a consulting fee from Roche Diagnostics, Prothena and Merck.